Filing Details
- Accession Number:
- 0001104659-22-005558
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-19 18:25:48
- Reporting Period:
- 2022-01-14
- Accepted Time:
- 2022-01-19 18:25:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1442836 | Mersana Therapeutics Inc. | MRSN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709775 | B Timothy Lowinger | C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139 | Chief Science & Tech Off. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-14 | 15,209 | $0.00 | 135,975 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-01-18 | 4,741 | $5.92 | 131,234 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2022-01-14 | 7,917 | $0.00 | 7,917 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2022-01-14 | 7,292 | $0.00 | 7,292 | $0.00 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2022-01-14 | 86,250 | $0.00 | 86,250 | $6.28 |
| Common Stock | Restricted Stock Units | Acquisiton | 2022-01-14 | 19,167 | $0.00 | 19,167 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,833 | No | 4 | M | Direct | ||
| 21,875 | No | 4 | M | Direct | ||
| 86,250 | 2032-01-13 | No | 4 | A | Direct | |
| 19,167 | No | 4 | A | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting.
- Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales weremandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholdingobligations and does not represent a discretionary trade by the reporting person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.82 to $5.92, inclusive. The reporting personundertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, fullinformation regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- 50% of the total number of RSUs vested as of January 14, 2022, and thereafter shall vest in equal annual installments over the next two years.
- 25% of the total number of RSUs vested on January 14, 2022, and thereafter shall vest in equal annual installments over the next three years.
- The option vests in equal quarterly installments over the first four years after the vesting commencement date, January 14, 2022.
- The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022.
Billionaire Hedge Funds
